TrialJournal of Parkinson's disease2020

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.

Daryl DeKarske et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.